abs178.txt	background		aromatase	inhibitors	are	the	mainstay	of	therapy	for	patients	withhormone	receptor-positive	breast	cancer	in	both	adjuvant	and	metastatic	settings	their	use	in	clinical	practice	has	been	challenged	by	significantinter-individual	variability	in	response	and	tolerability		hence		the	purpose	ofthis	paper	is	to	provide	a	succinct	review	of	the	literature	on	the	geneticfactors	contributing	to	this	variability	design		a	systematic	search	in	pubmed	was	conducted	to	identify	studies	thatinvestigated	the	association	between	germline	polymorphisms	and	disposition	clinical	response	and	toxicities	of	aromatase	inhibitors		as	well	as	thoseevaluating	the	implications	of	mutations	in	esr1	on	clinical	response	results		polymorphisms	in	genes	coding	for	phase	i	and	phase	ii	enzymes(pharmacokinetic	genes)	significantly	modulated	exposure	to	aromatase	inhibitors	however		there	is	a	paucity	of	data	linking	interindividual	variability	in	drugexposure	to	clinical	response		furthermore		pharmacogenetic	studies	interrogatingrelationship	between	polymorphisms	in	cyp19a1	(the	target	site	of	aromataseinhibitors		i	e		a	pharmacodynamic	gene)	and	response	yielded	conflictingresults		acquired	mutations	in	esr1	receptors	have	been	identified	as	theunderlying	mechanism	of	resistance	to	aromatase	inhibitors		and	likely	predictdrug	response		although	some	pharmacogenetic	studies	have	implicatedpolymorphisms	in	cyp19a1	and	esr1	with	drug-related	side	effects		the	putativerole	of	these	genes	in	predicting	toxicity	warrants	further	validation	conclusion		genetic	polymorphisms	in	pharmacokinetic	and	pharmacodynamic	genesappear	to	influence	aromatase	inhibitor	disposition		response	and/or	toxicity	however		prospective	interventional	studies	are	needed	to	understand	theapplication	of	genomics	to	personalize	aromatase	inhibitor	therapy	in	breastcancer	patients	
